The primary purpose of Adenosine Bedford is to provide two distinct therapeutic benefits. This medication is used in situations involving certain distressing symptoms of Supraventricular Tachycardia (SVT), including sudden, acute episodes (PSVT). It helps address symptom clusters that may become intense or disruptive, such as the rapid and irregular heart palpitations that interfere with daily functioning. The core therapeutic benefit is that it is used for managing the rapid heart rhythm and may help patients cope more steadily with symptom fluctuations.

---

Supportive Management for Urinary Comfort and Diuresis

This product is commonly used across domains where supportive symptomatic assistance is needed for urinary tract health. It is relevant in conditions characterized by periods of heightened symptoms related to fluid balance and the potential for urolithiasis (kidney stone formation). It is applied in addressing symptoms that create noticeable physiological strain, such as painful urination (dysuria) and general urinary tract discomfort. This contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

---

Quick Fact: Therapeutic Domains

Domain	Symptom Axis	Contextual Use
Acute Cardiac Rhythms	Symptoms related to heightened physiological activity	Applied in clinical settings that involve acute or unstable symptom patterns
Urological Support	Symptoms related to physical discomfort	Relevant when supportive symptom management is appropriate
Diagnostic Aid	Symptoms that create noticeable physiological strain	Applied in scenarios where additional management of discomfort is required

Regulatory References

1. NIH StatPearls overview of Adenosine

Eligibility Map: Who can and cannot use Adenosine Bedford — Official Regulatory Information

The eligibility for Adenosine Bedford is dictated by the potent Adenosine component. Eligibility is established for adults but is highly constrained by pre-existing cardiac and respiratory conditions.

---

Populations for whom use is Contraindicated

Classification	Rule (Must Not Use)
Severe Conduction Defects	Second- or Third-Degree AV Block or Sick Sinus Syndrome (unless a functioning pacemaker is present).
Respiratory Disease	Known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma).
Other Cardiac Issues	Long QT Syndrome, Severe Hypotension, or decompensated states of heart failure.

---

Age-Related and Conditional Eligibility Status

Population Group	Regulatory Status
Pediatric Patients (0-18 yrs)	Safety and efficacy have not been formally established in controlled clinical studies (EMA/HPRA).
Older Adults (Geriatric)	Use with caution is required due to the potential for diminished cardiac function or concomitant disease.
Pregnancy Status	FDA Category C. Use only if clearly needed; potential benefits must outweigh fetal risks.
Renal/Hepatic Status	No specific dosage adjustment or restriction is typically required.

These official rules strictly define who is allowed to receive the medicine, primarily excluding those with absolute cardiovascular or respiratory contraindications, and imposing cautions based on age and reproductive status.

Interactions with other medicines and products

The interaction profile of this medicine focuses strictly on the Adenosine component, which involves pharmacodynamic and nucleoside transport mechanisms detailed in government regulatory documents.

Interaction Scope

Property	Official Regulatory Statement
Medicinal product categories with documented interactions:	Methylxanthine agents, Nucleoside Transport Inhibitors, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, and Cardiac Glycosides.
Specific interacting medicines (if explicitly listed):	Dipyridamole, Theophylline, Caffeine, and Carbamazepine.
Mechanistic basis of interactions (only if stated in label):	Receptor Antagonism, Nucleoside Transport Inhibition, and Additive/Synergistic Pharmacodynamic Depression.
Interaction-related restrictions:	Contraindicated co-administration with Dipyridamole. Mandatory withholding of Methylxanthines (e.g., Caffeine, Theophylline).

---

Official Interaction Statements

• Dipyridamole is a contraindicated combination because it inhibits nucleoside transport, thereby potentiating the activity of Adenosine.
• Methylxanthines are receptor antagonists that inhibit the vasoactive effects of Adenosine. These agents should be withheld for at least five half-lives prior to Adenosine use, when possible.
• Cardioactive agents such as Beta-blockers and Calcium Channel Blockers may produce additive or synergistic depressant effects on the heart's electrical nodes.

The official regulatory profile is defined by interactions that fall into distinct classes of pharmacodynamic augmentation and clearance alteration. This structure mandates specific prohibitions and timing-based separation requirements as defined in government drug labeling.

Adenosine Bedford acts as an agonist with a primary target of the adenosine A1 receptors (A1AR), predominantly expressed in the sinoatrial (SA) and atrioventricular (AV) nodal tissues of the heart. The A1AR is a G-protein-coupled receptor (GPCR) linked to the inhibitory G-protein ( G i).

Activation of the G i protein triggers two distinct intracellular pathways: inhibition of adenylyl cyclase (AC) and direct activation of K^+ channels. The AC inhibition leads to a rapid decrease in intracellular cyclic AMP (cAMP), which, in turn, reduces the open probability of L-type calcium ( Ca^2+) channels. Simultaneously, the G i protein's betagamma subunits directly activate inwardly rectifying potassium ( K^+) channels ( I K,Ado).

These molecular events result in a downstream cascade of cellular hyperpolarization due to increased K^+ efflux and a reduction in Ca^2+ influx. The resulting change in membrane potential and suppression of the Ca^2+-dependent action potential leads to a system-level physiological consequence of decreased conduction velocity and an increased refractory period within the AV node, and a reduction in the spontaneous firing rate of the SA node.

How to Use Adenosine Bedford

The administration of Adenosine Bedford involves two distinct administration protocols, reflecting the highly regulated synthetic component and the traditional natural component.

Administration Protocol: Adenosine Component (IV)

The Adenosine component is administered for acute use as a rapid intravenous (IV) bolus or as an IV Infusion for diagnostic purposes. For the rapid IV bolus, the standard adult regimen begins with an initial dose of 6 mg. If the desired effect is not achieved within one to two minutes, a second dose of 12 mg may follow, with a third 12 mg dose permissible after another one to two minutes, up to a maximum total of 30 mg per acute episode.

Administration requires a specialized technique: the dose must be administered over one to two seconds and followed immediately by a rapid saline flush (e.g., 20 mL) into the vein closest to the central circulation. This technique is necessary due to the substance's extremely short half-life.

Administration Protocol: Aervae Lanatae Herba Component (Oral)

The Aervae Lanatae Herba component is administered via the oral route, typically prepared as an Infusion or Decoction. Usage involves preparing a liquid from the raw material and administering it up to three times per day (TID) for a short-term course. The prepared liquid has a limited stability and must be used within 48 hours of its preparation, requiring a fresh batch for any extended period of use.

Population-Specific Use

Official prescribing information mandates dose adjustment for pediatric patients weighing less than 50 kg, utilizing a weight-based dose (e.g., 0.05 to 0.1 mg/kg initial), which differs from the standard adult dose used for pediatric patients weighing 50 kg or more.

Research evidence / Overview of studies for Adenosine Bedford

---

Evidence for Acute Management of Paroxysmal Supraventricular Tachycardia (PSVT)

Adenosine, the synthetic component of this medicine, was studied to evaluate its action in Paroxysmal Supraventricular Tachycardia (PSVT) episodes, which are conditions associated with acute or disruptive episodes of a rapid heart rhythm. The primary research exploring this was evaluated in a large number of Randomized Controlled Trials (RCTs) and meta-analyses that compared its use against other interventions. These studies typically involved adults experiencing episodes of PSVT. Research examined the rate of observed change toward a normal rhythm following administration.

Studies focused on the short-term, episodic nature of the condition. Findings from multiple trials described patterns where a rapid heart rhythm change was observed in the study populations. The evidence describes patterns observed in acute care settings. Research also explored the drug's use as a diagnostic aid to categorize certain rapid heart rhythms.

---

Research Base for Supportive Urinary and Urolithiasis Management

The evidence base for the natural component, Aervae Lanatae Herba, relating to supportive management for urinary comfort and urolithiasis (kidney stone) formation, follows a different research path. Studies exploring this component’s traditional uses are primarily preclinical, meaning the research was conducted using animal models and laboratory (in vitro) settings. These studies examined outcomes related to systemic or functional imbalance, such as crystal formation or changes in urine volume, to see how the component was associated with traditional claims.

While preclinical research describes patterns where biological activity related to diuretic effects and crystal aggregation outcomes was observed in animals, evidence remains limited regarding large-scale, high-quality human trials. These findings provide context for patterns observed in research, but data show patterns related to non-human or laboratory models, and certainty remains low for describing effects in humans.

---

Evidence Gaps and Areas of Uncertainty

A review of the available research highlights several key areas where research is ongoing or where certainty remains low. A significant gap exists regarding long-term effects for both components; the acute nature of Adenosine's use means that long-term outcomes are not fully established, and follow-up durations were limited.

A key limitation is that the primary evidence for the natural component is derived from settings with varying symptom burdens and reliance on animal models. The evidence quality varies across studies for this traditional component, and large-scale RCTs that meet current regulatory standards for supportive use are not available. Findings describe group patterns, not personal outcomes, and research does not provide individual predictions.

Key Studies & References

1. Preventive and therapeutic effects of Aerva lanata (L.) extract on ethylene glycol-induced nephrolithiasis in male Wistar albino rats
2. Adult Tachycardia With a Pulse Algorithm - American Heart Association CPR and First Aid (Clinical Guideline)

Common questions about Adenosine Bedford (FAQ)

Q: How quickly does the effect of Adenosine Bedford begin after administration?

According to official product information, the Adenosine component is administered rapidly, typically over one to two seconds. This specialized technique is required because the substance has an extremely short half-life, meaning its effect is rapid but quickly subsides.

Q: How long does the main therapeutic effect of Adenosine Bedford usually last?

The official product information states that the drug has an extremely short half-life. This means that both the main therapeutic effect and the temporary side effects are very transient, or short-lived, immediately following administration.

Q: What types of heart rhythm problems is Adenosine Bedford indicated for?

Official regulatory documents state that the Adenosine component is indicated for the rapid correction of episodes of Paroxysmal Supraventricular Tachycardia (PSVT). This is a specific type of rapid heart rhythm problem.

Q: Are there any known long-term side effects associated with receiving Adenosine Bedford?

Because the Adenosine component is typically used for acute, short-term episodes, long-term effects are not fully established in official research. Regulatory notes also caution that prolonged or long-term exposure to the herbal component may require consideration for potential structural changes in the urinary tract.

Q: What kind of studies examine the use of Adenosine Bedford in specific patient populations?

Research examining the acute use of the Adenosine component primarily involves adults experiencing PSVT. Official labeling indicates that safety and efficacy have not been formally established in pediatric patients in controlled clinical studies.

Q: What are the typical ingredients or components (other than the active drug) in Adenosine Bedford?

The product is officially defined by its two active components: synthetic Adenosine and natural Aervae Lanatae Herba. During the administration of the IV component, a rapid saline flush is used as part of the specialized injection technique.

Q: Are there specific types of herbal supplements known to interact with Adenosine Bedford?

The official interaction profile focuses on mandatory interactions with medicinal categories like Methylxanthines (found in some herbal sources like coffee, tea, and some supplements) and Nucleoside Transport Inhibitors. Regulatory documents do not provide a general blanket statement regarding all other herbal supplements.

Q: Is Adenosine Bedford the same medication as Adenoscan or other forms of Adenosine?

The product is defined as a specialized Combination Product that integrates the synthetic component Adenosine with the natural component Aervae Lanatae Herba. This classification means it is a specific, regulated formulation distinct from generic Adenosine or other brand-specific products.

Q: Does Adenosine Bedford require special patient monitoring immediately after it is given?

Due to the drug's rapid action profile and the potential for documented serious adverse reactions (such as cardiac arrest), the administration must occur in a controlled medical setting. This setting supports immediate access to monitoring and life support capabilities.

Q: What does the term 'contraindication' mean regarding the use of this drug?

A contraindication is an official rule from regulatory authorities stating that the medicine is officially prohibited from being used in patients who have specific pre-existing conditions. For this drug, these include conditions like asthma or high-grade heart block, as use in these cases carries a documented significant risk.

Q: How does the medicine get broken down and cleared from the body?

Regulatory information emphasizes the drug’s extremely short half-life and rapid clearance from the body. The substance is quickly absorbed into the cells where it is rapidly broken down by enzymes into inactive metabolites.

Q: What information is legally required to be on the official label of Adenosine Bedford?

Official labels are legally required to provide comprehensive safety and usage information. This includes detailed information on medicinal product categories with documented interactions, the frequency of common adverse reactions, and a description of serious adverse reactions.

Q: Is this medication known by any other common names?

Official documents identify the synthetic component as Adenosine, which is the internationally recognized generic name for the active ingredient. The product is known by its registered brand name, such as Adenosine Bedford, or its established component name.

Q: What should a patient expect to feel after the transient effects of the drug wear off?

Because the drug's effects are described as very transient, once the short-lived common adverse reactions (such as flushing or chest discomfort) subside, the patient is described as typically returning to their baseline status prior to administration.

Q: How often is Adenosine Bedford typically used in emergency medical services?

The drug is officially administered for acute use in controlled medical settings. Its evidence base is derived from research on acute episodes of Paroxysmal Supraventricular Tachycardia (PSVT), which are conditions often managed in emergency care settings.

Q: Does having low blood volume (hypovolemia) relate to receiving this medication?

Official prescribing information includes a contraindication for patients with Severe Hypotension (very low blood pressure). This is one of the circulatory status conditions that regulatory documents address concerning the drug’s safe use.

How to Store and Dispose of Adenosine Injection

Official regulatory information requires that this medication be stored within a controlled room temperature range, typically 20 to 25 C (68 to 77 F), and must not be stored above 25 C.

Do not refrigerate Adenosine, as cold temperatures may cause the solution to crystallize. If crystallization does occur, the product should be warmed to room temperature to redissolve the solids prior to use.

Handling and Disposal

• Visual Inspection: Before use, the solution must be visually inspected to ensure it is clear, colorless, and free of particulate matter.
• Single-Use Container: The vial is intended for single use only.
• Disposal: Any unused portion of the injection, along with the container, must be discarded and disposed of immediately in accordance with local regulatory requirements.